Cochrane Review Group

HIV/AIDS

36 systematic reviews in HIV/AIDS ask 473 questions. 8% have no studies to answer them, 26.6% rest on very low certainty evidence and 36.5% reach moderate or high certainty.

Reviews

Questions

473

current versions

No studies

Moderate or high

36.5%

No studies 38 · 8%Ungraded 9 · 1.9%Very low 126 · 26.6%Low 127 · 26.8%Moderate 152 · 32.1%High 21 · 4.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in HIV/AIDS

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Bleomycin vs ABV Mortality · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 1.09 [0.87, 1.36]	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ complete response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	no estimate extracted	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ partial response · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.11 [0.01, 1.86]	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ stable disease · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 0.88 [0.47, 1.63]	1 study · 24 participants	Very low
Bleomycin vs ABV Clinical response ‐ progression · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 11 [0.67, 179.29]	1 study · 24 participants	Very low
Bleomycin vs ABV Adverse events · HIV‐infected adults with severe (T1) Kaposi's sarcoma Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults (2014) · Cochrane	RR 11 [0.67, 179.29]	1 study · 24 participants	Very low
Doctor vs nurse or clinical officer Lost to · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.34 [0.18, 0.66]	1 study · 2772 participants	Very low
Doctor vs nurse or clinical officer Death or loss to · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.3 [0.17, 0.54]	1 study · 2772 participants	Very low
Doctor vs community health worker Outcomes2 · HIV infected patients on antiretroviral therapy. Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	no estimate extracted	NR	No studies
Doctor vs nurse or clinical officer Lost to · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.3 [0.05, 1.94]	2 studies · 39156 participants	Very low
Doctor vs nurse or clinical officer Death or loss to · HIV‐infected patients Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.72 [0.48, 1.07]	2 studies · 39160 participants	Very low
Doctor vs nurse or clinical officer Death (Cohorts) · HIV infected patients on antiretroviral therapy Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy (2014) · Cochrane	RR 0.19 [0.05, 0.78]	1 study · 2772 participants	Very low

Reviews 36

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection

Ewald, H, Raatz, H, et al. · Cochrane Database of Systematic Reviews · 2015

HIV/AIDS

Thinnest evidence

Reviews 36

Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection

Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults

Structural and community‐level interventions for increasing condom use to prevent the transmission of HIV and other sexually transmitted infections

Task shifting from doctors to non‐doctors for initiation and maintenance of antiretroviral therapy

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection

Treatment of Kaposi sarcoma in children with HIV‐1 infection

Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection

Yellow fever vaccine for patients with HIV infection

Antiretroviral interventions for preventing breast milk transmission of HIV

Nutritional interventions for reducing morbidity and mortality in people with HIV

Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS

Abacavir‐based triple nucleoside regimens for maintenance therapy in patients with HIV

Antiretroviral therapy for prevention of HIV transmission in HIV‐discordant couples

Telephone delivered interventions for reducing morbidity and mortality in people with HIV infection

Decentralising HIV treatment in lower‐ and middle‐income countries

Optimal time for initiating antiretroviral therapy (ART) in HIV‐infected, treatment‐naive children aged 2 to 5 years old

Micronutrient supplementation for children with HIV infection

Behavioral interventions to reduce the transmission of HIV infection among sex workers and their clients in low‐ and middle‐income countries

Antiretroviral pre‐exposure prophylaxis (PrEP) for preventing HIV in high‐risk individuals

Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV

Topical treatments for HIV‐related oral ulcers

Motivational interviewing for improving outcomes in youth living with HIV

Micronutrient supplementation in pregnant women with HIV infection

Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection

Treatment for anemia in people with AIDS